CRYSTALGENOMICS

Company Introduction:

CRYSTALGENOMICS is a leading South Korean biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative new drugs. Founded in 2000, the company leverages its proprietary structure-based drug discovery technology to develop novel therapeutic candidates for unmet medical needs. Their primary focus areas include inflammatory diseases, infectious diseases, and oncology. They have successfully brought products to market, demonstrating their capabilities across the entire drug development pipeline, from initial research to manufacturing and commercialization.

Business Type: Manufacturer/Developer

Explanation:

CRYSTALGENOMICS is primarily a manufacturer and developer. As a biopharmaceutical company, it conducts extensive research and development (R&D) to discover new drug candidates. It then proceeds with clinical trials and, upon regulatory approval, manufactures its own pharmaceutical products or oversees their manufacturing through contract manufacturing organizations (CMOs) to bring them to market. It is not a trading company that solely buys and sells existing goods from other entities. Their core business involves the creation and production of proprietary medicines.

Here are some of the products manufactured or sold by CrystalGenomics:

* Camostat mesilate (for pancreatitis)

* Acelex (osteoarthritis treatment)

* CG-549 (fibrosis treatment - in development)

* CG-750 (acute myeloid leukemia (AML) treatment - in development)

* Various diagnostic reagents and research chemicals